Beta Bionics receives FDA clearance for Mint patch pump
Beta Bionics says its Mint patch pump received FDA clearance, it filed its 3D dosing algorithm, and it formed a Senseonics Eversense 365 CGM partnership. The company trimmed 2026 revenue guidance to $121–$126M and raised $172.5M ahead of a full Mint U.S. launch planned for Q1 2027.
Beta Bionics, Inc. (NASDAQ:BBNX) secured FDA clearance for the Mint patch pump, filed its 3D dosing algorithm, and entered into a Senseonics Eversense 365 CGM partnership. S. launch in Q1 2027.